Abstract
cis-Diamminedichloroplatinum (II) (cis-DDP), the antitumor drug, is cytotoxic in vitro primarily by binding to DNA and disrupting its normal functions. We have studied cis-DDP modification of DNA in nucleated peripheral blood cells (buffy coat cells) of testicular and ovarian cancer patients receiving cis-DDP chemotherapy, and of untreated controls. Using a highly sensitive enzyme-linked immunosorbent assay (ELISA) with an antiserum specific for the bidentate intrastrand N7-deoxyguanosine adduct, blood cell DNA was assayed at multiple times during courses of cis-DDP treatment. A total of 138 samples were analyzed from 54 individuals. Of these, all samples from 18 untreated controls were negative, while 44 out of 120 samples from cis-DDP patients were positive. Testicular and ovarian cancer patients receiving chemotherapy on the first course, and given cis-DDP in 21- or 28-day cycles (five days of drug infusion followed by two or three drug-free weeks) accumulated cis-DDP-DNA adducts in blood cell DNA as a function of dose. Patients receiving their first course of cis-DDP on 56-day cycles and those given high doses of this drug after failing other chemotherapy showed much slower adduct accumulation than patients receiving their first course on 21- or 28-day cycles. Adduct accumulation, in positive patients, occurred both as a function of total cumulative dose and with increasing cycle number, suggesting that adduct removal took at least a month in these patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Fichtinger-Schepman A. M., Lohman P. H., Reedijk J. Detection and quantification of adducts formed upon interaction of diamminedichloroplatinum (II) with DNA, by anion-exchange chromatography after enzymatic degradation. Nucleic Acids Res. 1982 Sep 11;10(17):5345–5356. doi: 10.1093/nar/10.17.5345. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Johnson D. C., Luedke D. W., Sapiente R. A., Naidu R. G. Acute lymphocytic leukemia developing in a male with germ cell carcinoma: a case report. Med Pediatr Oncol. 1980;8(4):361–365. doi: 10.1002/mpo.2950080407. [DOI] [PubMed] [Google Scholar]
- Mead G. M., Green J. A., Macbeth F. R., Williams C. J., Whitehouse J. M., Buchanan R. Second malignancy after cisplatin, vinblastine, and bleomycin (PVB) chemotherapy: a case report. Cancer Treat Rep. 1983 Apr;67(4):410–410. [PubMed] [Google Scholar]
- Müller R., Rajewsky M. F. Elimination of O6-ethylguanine from the DNA of brain, liver, and other rat tissues exposed to ethylnitrosourea at different stages of prenatal development. Cancer Res. 1983 Jun;43(6):2897–2904. [PubMed] [Google Scholar]
- Plooy A. C., van Dijk M., Lohman P. H. Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. Cancer Res. 1984 May;44(5):2043–2051. [PubMed] [Google Scholar]
- Poirier M. C. Antibodies to carcinogen-DNA adducts. J Natl Cancer Inst. 1981 Sep;67(3):515–519. [PubMed] [Google Scholar]
- Poirier M. C., Lippard S. J., Zwelling L. A., Ushay H. M., Kerrigan D., Thill C. C., Santella R. M., Grunberger D., Yuspa S. H. Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro. Proc Natl Acad Sci U S A. 1982 Nov;79(21):6443–6447. doi: 10.1073/pnas.79.21.6443. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Young R. C., Von Hoff D. D., Gormley P., Makuch R., Cassidy J., Howser D., Bull J. M. cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1539–1544. [PubMed] [Google Scholar]
- Zwelling L. A., Anderson T., Kohn K. W. DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res. 1979 Feb;39(2 Pt 1):365–369. [PubMed] [Google Scholar]